China approves the world’s first CAR-T cell therapy for gastric cancer
China has approved Kaileimei (Satri-cel, CT041), the world’s first CAR-T cell therapy for solid tumors. The innovative CLDN18.2-targeted treatment offers a new option for patients with advanced gastric and gastroesophageal junction cancer who have failed at least two prior lines of therapy.
A New Step Forward: CAR-T Therapy for Gastric Cancer Included in China’s CSCO Guidelines
A new CAR-T therapy for advanced gastric cancer has been recognized in China’s national clinical guidelines, offering a potential new option for patients with limited treatment choices.